INDOCO258.00

Indoco Remedies Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersSAIPARENTPANACEABIOHIKALWINDLASHESTERBIODCALSYNCOMFSOLARAMcap ₹2,381 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q2 FY24
30/09/2023
Q3 FY24
31/12/2023
Q4 FY24
31/03/2024
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations481.7459.4449.6431.5432.7410.6390.2437.9484.7445.4475.6467.5
Other Income4.42.42.71.01.60.92.01.60.81.0-0.02.2
Total Income486.2461.8452.3432.5434.2411.4392.2439.5485.4446.3475.6469.7
Expenses
+ Cost of Materials Consumed130.9129.3121.8106.294.3109.985.9105.5113.097.9109.2104.6
+ Purchases of Stock-in-Trade25.730.627.236.239.234.930.639.238.833.032.539.9
+ Changes in Inventories-9.4-17.6-8.1-1.03.4-30.9-10.5-9.8-6.5-10.5-0.713.6
+ Employee Benefit Expense92.190.088.397.392.997.6106.4107.0103.2106.0109.4101.4
+ Finance Costs8.110.112.114.317.816.118.026.124.625.645.928.3
+ Depreciation & Amortisation21.424.426.227.528.828.728.829.732.332.032.534.5
+ Other Expenses170.9164.2171.6145.0162.7187.1178.7178.4193.1187.4175.5167.0
Total Expenses439.9430.9439.1425.6439.1443.4437.8476.2498.4471.5504.3489.3
EBITDA71.462.948.947.840.312.0-0.817.543.131.549.741.0
EBIT50.038.622.620.311.4-16.7-29.6-12.210.8-0.517.26.5
Profit
PBT before Exceptional Items46.330.813.37.0-4.8-32.0-45.5-36.7-13.0-25.2-28.7-19.6
+ Exceptional Items0.0-8.219.70.00.01.00.00.0-0.5-6.23.797.3
Pretax Income46.322.633.07.0-4.8-31.0-45.5-36.7-13.5-31.3-25.077.7
+ Current Tax11.72.310.74.83.4-5.0-2.70.00.10.03.010.6
+ Deferred Tax-0.64.80.30.31.82.4-1.5-0.3-4.4-1.9-4.31.7
Tax Expense11.07.111.05.25.2-2.6-4.2-0.3-4.3-1.9-1.312.3
Net Income35.215.622.01.8-10.0-28.4-41.3-36.4-9.2-29.5-23.765.4
+ Net Income — Continuing Ops35.215.622.01.8-10.0-28.4-41.3-36.4-9.2-29.5-23.765.4
+ Other Comprehensive Income-0.2-0.10.8-0.1-1.0-0.1-2.9-0.22.6-1.311.40.7
Total Comprehensive Income35.015.522.91.7-11.0-28.5-44.3-36.5-6.6-30.7-12.266.1
Net Income to Common35.116.322.72.6-9.6-26.4-40.4-35.8-7.9-29.8-21.665.0
Minority Interest0.2-0.7-0.7-0.8-0.4-2.0-1.0-0.6-1.30.3-2.00.5
Per Share
Basic EPS3.821.692.390.20-1.09-3.08-4.48-3.94-1.00-3.20-2.577.09
Diluted EPS3.821.692.390.20-1.08-3.08-4.48-3.94-1.00-3.19-2.567.09
Other Comprehensive Income — detail
+ Other Comprehensive Income-2.9-0.22.6-1.311.40.7
+ Items NOT to be Reclassified to P&L-0.3-0.31.0-0.3-0.3-0.3-5.1-0.8-0.8-0.84.1-0.6
+ Tax on Items NOT to be Reclassified-1.3-0.2-0.2-0.21.0-0.2
+ Tax on Items NOT to be Reclassified — alt tag-0.1-0.10.2-0.1-0.1-0.1
+ Items to be Reclassified to P&L0.00.10.10.1-1.00.11.00.93.7-0.58.61.2
+ Tax on Items to be Reclassified0.10.50.50.20.20.0
+ Tax on Items to be Reclassified — alt tag0.00.00.00.0-0.20.0
Comprehensive Income — Owners of Parent34.916.223.52.5-10.6-26.5-43.3-36.0-5.4-31.1-10.265.7
Comprehensive Income — Non-controlling Interests0.2-0.7-0.7-0.8-0.4-2.0-1.0-0.6-1.30.3-2.00.5
Per Share — as-filed variants
Basic EPS — Continuing Operations3.821.692.390.20-1.09-3.08-4.48-3.94-1.00-3.20-2.577.09
Diluted EPS — Continuing Operations3.821.692.390.20-1.08-3.08-4.48-3.94-1.00-3.19-2.567.09
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit334.4317.1308.8290.0295.9296.6284.2302.9339.3324.9334.6309.5
Gross Margin %69.4269.0268.6767.2168.3872.2572.8469.1870.0172.9670.3566.19
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)46.330.813.37.0-4.8-32.0-45.5-36.7-13.0-25.2-28.7-19.6
− Exceptional Items (reconciliation)0.0-8.219.70.00.01.00.00.0-0.5-6.23.797.3
Net Income Adj (tax-effected)35.221.28.91.8-10.0-29.3-41.3-36.4-8.8-23.7-27.2-16.5
EPS Adj3.822.300.960.20-1.09-3.18-4.48-3.94-0.96-2.57-2.95-1.79
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value2.002.002.002.002.002.002.002.002.002.002.002.00
Paid Up Equity Capital18.418.418.418.418.418.418.518.518.518.518.518.5
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.